Pharmaceutical Sales Certification (PSC) Pharmacy
Sales Rep Cert
1. A pharmaceutical sales representative is preparing a presentation for a hospital formulary
committee on a new anticoagulant. The drug shows a 30% relative risk reduction in stroke
compared to warfarin, but the absolute risk reduction is only 1.2%. The number needed to treat
(NNT) is approximately 83. The representative wants to highlight the drug's efficacy. Which of the
following statements is most accurate and compliant with FDA guidelines on fair balance in
promotional materials?
A. The drug reduces stroke risk by 30%, making it significantly more effective than warfarin.
B. The drug prevents one stroke for every 83 patients treated, compared to warfarin.
C. The absolute risk reduction of 1.2% indicates a modest benefit over warfarin.
D. The relative risk reduction of 30% is the most clinically meaningful measure for patients.
Answer: B
Rationale: Correct: Option B presents the NNT, which is a balanced and clinically relevant measure.
Option A overemphasizes relative risk without context, which can be misleading. Option C is accurate
but may understate benefit in a promotional context. Option D disregards fair balance by favoring
relative risk. FDA guidance requires presenting both absolute and relative risk or using NNT to avoid
misleading claims.
2. A pharmaceutical company is launching a new biologic for psoriasis. The drug is a monoclonal
antibody that inhibits IL-17. During a sales call, a dermatologist asks about the potential for
immunogenicity and its impact on efficacy and safety. Which of the following responses is most
accurate based on current scientific understanding and regulatory labeling requirements?
A. Immunogenicity is rare with fully human monoclonal antibodies, and any neutralizing antibodies do not
affect efficacy significantly.
B. The incidence of anti-drug antibodies is low, but if present, they may reduce efficacy and increase infusion
reactions; the label includes this information.
C. Immunogenicity is not a concern for this class of biologics because IL-17 inhibitors are small molecules.
D. The drug is designed to avoid immunogenicity, and no antibody testing is required during clinical trials.
Answer: B
Rationale: Correct: Option B accurately states that immunogenicity can occur and may impact efficacy
and safety, and that labeling must disclose this. Option A is incorrect because even fully human
antibodies can elicit immune responses. Option C is false; IL-17 inhibitors are biologics, not small
molecules. Option D is incorrect; clinical trials routinely monitor for anti-drug antibodies.
Page 1
,3. A sales representative is analyzing a pharmacy benefit manager's (PBM) formulary tier
placement for a new oral diabetes medication. The PBM has placed the drug on Tier 3 (preferred
brand) with a prior authorization requirement. The representative wants to increase utilization.
Which of the following strategies is most likely to be effective and compliant with anti-kickback
statutes?
A. Offer the PBM a volume-based rebate tied to market share growth, structured as a discount on list price.
B. Provide free drug samples to the PBM's network physicians to encourage prescribing.
C. Sponsor a continuing medical education (CME) program on diabetes management with an unrestricted
educational grant.
D. Pay a copay assistance program for patients to reduce out-of-pocket costs, without income verification.
Answer: A
Rationale: Correct: Volume-based rebates structured as discounts are generally permissible under the
Anti-Kickback Statute if properly disclosed and not tied to specific patients. Option B may implicate the
federal Anti-Kickback Statute as free samples can induce prescribing. Option C is permissible but
indirect and may not directly address tier placement. Option D could violate the Anti-Kickback Statute if
it is used to induce the use of a particular drug without regard to medical necessity.
4. In a sales training session, a manager discusses the importance of understanding the 'buying
center' in a large academic medical center. Which of the following best describes the composition of
the buying center for a new oncology drug, considering the roles of various stakeholders?
A. The pharmacy and therapeutics (P&T) committee alone makes the formulary decision; prescribers and
patients have no formal role.
B. The buying center includes the P&T committee, key prescribers (oncologists), pharmacy directors, and
financial administrators; each has distinct influence on adoption.
C. Only the hospital CEO and chief financial officer decide on drug adoption based on budget impact.
D. The buying center is limited to the medical director and the pharmacy director; other stakeholders are
consulted but not decision-makers.
Answer: B
Rationale: Correct: In large institutions, the buying center is multi-disciplinary, including P&T
committee, prescribers, pharmacy, and finance. Option A is too narrow; prescribers and patients
influence decisions indirectly. Option C is incorrect because clinical input is crucial. Option D
underestimates the role of the P&T committee and other stakeholders.
5. A sales representative is presenting a new antihypertensive drug that combines an ACE inhibitor
and a thiazide diuretic. The representative claims that the combination has a synergistic effect on
blood pressure reduction. Which of the following physiological mechanisms best explains the
synergy between these two classes?
A. ACE inhibitors increase renin release, while thiazides inhibit aldosterone secretion, leading to additive
natriuresis.
B. Thiazides cause volume depletion, which activates the renin-angiotensin-aldosterone system; ACE inhibitors
block this compensatory response.
C. ACE inhibitors directly dilate renal afferent arterioles, while thiazides constrict efferent arterioles, increasing
glomerular filtration rate.
D. Both drugs inhibit the same enzyme, leading to a cumulative effect on angiotensin II levels.
Page 2
,Answer: B
Rationale: Correct: Thiazide diuretics reduce plasma volume, activating the RAAS. ACE inhibitors block
the conversion of angiotensin I to II, blunting the compensatory vasoconstriction and aldosterone
release, resulting in greater BP reduction. Option A is incorrect because ACE inhibitors decrease renin
release due to negative feedback. Option C is incorrect; ACE inhibitors dilate efferent arterioles. Option
D is false; they act on different targets.
6. A pharmaceutical company is developing a digital companion app for a new asthma inhaler. The
app tracks medication adherence and provides reminders. The representative is discussing the app
with a physician. Which of the following statements about the regulatory status of such digital tools
is most accurate?
A. The app is considered a medical device and requires FDA clearance before marketing.
B. The app is exempt from FDA regulation because it only provides adherence reminders and does not make
treatment recommendations.
C. The app is classified as a drug-device combination product and must be approved via a single application.
D. The app is regulated by the FTC, not the FDA, because it is a promotional tool.
Answer: B
Rationale: Correct: Under FDA guidance, apps that simply track adherence and provide reminders are
generally not regulated as medical devices, as they do not perform clinical functions. Option A is
incorrect unless the app makes diagnostic or therapeutic recommendations. Option C is incorrect
because it is not a combination product. Option D is incorrect; the FDA regulates software that meets
device definition.
7. A sales representative is preparing a report on the competitive landscape for a novel oral
anticoagulant. The representative needs to compare the drug's efficacy and safety profile to
warfarin and direct oral anticoagulants (DOACs). Which of the following study design features is
most critical for evaluating the drug's net clinical benefit?
A. A non-inferiority trial with a wide margin to demonstrate at least equivalent efficacy.
B. A superiority trial powered for both efficacy and safety endpoints, with a composite of stroke and major
bleeding as the primary outcome.
C. An observational cohort study with propensity score matching to reflect real-world effectiveness.
D. A meta-analysis of several small randomized trials to increase statistical power.
Answer: B
Rationale: Correct: A superiority trial with a composite endpoint of efficacy and safety (net clinical
benefit) provides the most robust evidence for comparing benefit-risk. Option A: non-inferiority with
wide margin may not demonstrate superiority and can be misleading. Option C: observational studies
are subject to confounding despite matching. Option D: meta-analyses can be useful but depend on
quality of included trials; a well-powered single trial is stronger.
8. A sales representative is calling on a rheumatologist who prescribes a biologic for rheumatoid
arthritis. The doctor mentions that several patients have developed neutralizing antibodies to the
drug, leading to loss of efficacy. The representative wants to suggest a strategy to mitigate
immunogenicity. Which of the following approaches is most evidence-based?
Page 3
, A. Switching to a biosimilar of the same biologic, which has lower immunogenicity due to minor structural
differences.
B. Concomitant use of methotrexate, which has been shown to reduce anti-drug antibody formation.
C. Increasing the dose of the biologic to overcome antibody-mediated clearance.
D. Administering the biologic subcutaneously instead of intravenously to reduce immune activation.
Answer: B
Rationale: Correct: Methotrexate is commonly used with biologics in RA and has been shown to reduce
immunogenicity, improving drug persistence. Option A is incorrect; biosimilars have similar
immunogenicity profiles. Option C is not a standard approach and may increase toxicity. Option D:
route of administration can affect immunogenicity, but switching from IV to SC does not consistently
reduce antibodies and may even increase them.
9. A pharmaceutical sales representative is preparing a value dossier for a new
cholesterol-lowering PCSK9 inhibitor. The drug reduces LDL cholesterol by 60% but costs $14,000
per year. The ICER (incremental cost-effectiveness ratio) compared to statins is $150,000 per
QALY gained. Which of the following statements best interprets the ICER and its implications for
formulary access?
A. An ICER of $150,000/QALY is below the commonly accepted US threshold of $200,000/QALY, so the drug
is likely to be covered without restrictions.
B. The ICER indicates the drug is not cost-effective, and payers will likely require prior authorization and
restrict use to high-risk patients.
C. The ICER is irrelevant because QALYs are not used by US payers in coverage decisions.
D. The ICER suggests the drug is cost-saving compared to statins when considering reduced cardiovascular
events.
Answer: B
Rationale: Correct: The commonly cited US cost-effectiveness threshold is around
$100,000-$150,000/QALY, so $150,000/QALY is borderline high, often leading to restricted access.
Option A is incorrect because many payers use lower thresholds. Option C is false; QALYs are used in
value assessments. Option D is incorrect; the drug is not cost-saving as it adds cost with modest QALY
gains.
10. A sales representative is planning a speaker program for a new migraine preventive drug. The
representative wants to ensure compliance with the PhRMA Code on Interactions with Healthcare
Professionals. Which of the following arrangements is most likely to be considered acceptable?
A. Hosting a dinner at a high-end restaurant for 20 physicians, with the representative presenting the drug's
clinical data.
B. Providing an unrestricted educational grant to a medical society to develop a CME program on migraine
management.
C. Paying a well-known neurologist a $5,000 honorarium to speak at a dinner program attended by 10 other
physicians.
D. Offering a $100 gift card to each physician who attends a webinar on the new drug.
Answer: B
Rationale: Correct: Unrestricted educational grants to medical societies for CME are generally
acceptable under the PhRMA Code. Option A: dinners must be modest and the setting should not be
extravagant. Option C: honoraria must be reasonable and not excessive; $5,000 for a small audience
Page 4
Sales Rep Cert
1. A pharmaceutical sales representative is preparing a presentation for a hospital formulary
committee on a new anticoagulant. The drug shows a 30% relative risk reduction in stroke
compared to warfarin, but the absolute risk reduction is only 1.2%. The number needed to treat
(NNT) is approximately 83. The representative wants to highlight the drug's efficacy. Which of the
following statements is most accurate and compliant with FDA guidelines on fair balance in
promotional materials?
A. The drug reduces stroke risk by 30%, making it significantly more effective than warfarin.
B. The drug prevents one stroke for every 83 patients treated, compared to warfarin.
C. The absolute risk reduction of 1.2% indicates a modest benefit over warfarin.
D. The relative risk reduction of 30% is the most clinically meaningful measure for patients.
Answer: B
Rationale: Correct: Option B presents the NNT, which is a balanced and clinically relevant measure.
Option A overemphasizes relative risk without context, which can be misleading. Option C is accurate
but may understate benefit in a promotional context. Option D disregards fair balance by favoring
relative risk. FDA guidance requires presenting both absolute and relative risk or using NNT to avoid
misleading claims.
2. A pharmaceutical company is launching a new biologic for psoriasis. The drug is a monoclonal
antibody that inhibits IL-17. During a sales call, a dermatologist asks about the potential for
immunogenicity and its impact on efficacy and safety. Which of the following responses is most
accurate based on current scientific understanding and regulatory labeling requirements?
A. Immunogenicity is rare with fully human monoclonal antibodies, and any neutralizing antibodies do not
affect efficacy significantly.
B. The incidence of anti-drug antibodies is low, but if present, they may reduce efficacy and increase infusion
reactions; the label includes this information.
C. Immunogenicity is not a concern for this class of biologics because IL-17 inhibitors are small molecules.
D. The drug is designed to avoid immunogenicity, and no antibody testing is required during clinical trials.
Answer: B
Rationale: Correct: Option B accurately states that immunogenicity can occur and may impact efficacy
and safety, and that labeling must disclose this. Option A is incorrect because even fully human
antibodies can elicit immune responses. Option C is false; IL-17 inhibitors are biologics, not small
molecules. Option D is incorrect; clinical trials routinely monitor for anti-drug antibodies.
Page 1
,3. A sales representative is analyzing a pharmacy benefit manager's (PBM) formulary tier
placement for a new oral diabetes medication. The PBM has placed the drug on Tier 3 (preferred
brand) with a prior authorization requirement. The representative wants to increase utilization.
Which of the following strategies is most likely to be effective and compliant with anti-kickback
statutes?
A. Offer the PBM a volume-based rebate tied to market share growth, structured as a discount on list price.
B. Provide free drug samples to the PBM's network physicians to encourage prescribing.
C. Sponsor a continuing medical education (CME) program on diabetes management with an unrestricted
educational grant.
D. Pay a copay assistance program for patients to reduce out-of-pocket costs, without income verification.
Answer: A
Rationale: Correct: Volume-based rebates structured as discounts are generally permissible under the
Anti-Kickback Statute if properly disclosed and not tied to specific patients. Option B may implicate the
federal Anti-Kickback Statute as free samples can induce prescribing. Option C is permissible but
indirect and may not directly address tier placement. Option D could violate the Anti-Kickback Statute if
it is used to induce the use of a particular drug without regard to medical necessity.
4. In a sales training session, a manager discusses the importance of understanding the 'buying
center' in a large academic medical center. Which of the following best describes the composition of
the buying center for a new oncology drug, considering the roles of various stakeholders?
A. The pharmacy and therapeutics (P&T) committee alone makes the formulary decision; prescribers and
patients have no formal role.
B. The buying center includes the P&T committee, key prescribers (oncologists), pharmacy directors, and
financial administrators; each has distinct influence on adoption.
C. Only the hospital CEO and chief financial officer decide on drug adoption based on budget impact.
D. The buying center is limited to the medical director and the pharmacy director; other stakeholders are
consulted but not decision-makers.
Answer: B
Rationale: Correct: In large institutions, the buying center is multi-disciplinary, including P&T
committee, prescribers, pharmacy, and finance. Option A is too narrow; prescribers and patients
influence decisions indirectly. Option C is incorrect because clinical input is crucial. Option D
underestimates the role of the P&T committee and other stakeholders.
5. A sales representative is presenting a new antihypertensive drug that combines an ACE inhibitor
and a thiazide diuretic. The representative claims that the combination has a synergistic effect on
blood pressure reduction. Which of the following physiological mechanisms best explains the
synergy between these two classes?
A. ACE inhibitors increase renin release, while thiazides inhibit aldosterone secretion, leading to additive
natriuresis.
B. Thiazides cause volume depletion, which activates the renin-angiotensin-aldosterone system; ACE inhibitors
block this compensatory response.
C. ACE inhibitors directly dilate renal afferent arterioles, while thiazides constrict efferent arterioles, increasing
glomerular filtration rate.
D. Both drugs inhibit the same enzyme, leading to a cumulative effect on angiotensin II levels.
Page 2
,Answer: B
Rationale: Correct: Thiazide diuretics reduce plasma volume, activating the RAAS. ACE inhibitors block
the conversion of angiotensin I to II, blunting the compensatory vasoconstriction and aldosterone
release, resulting in greater BP reduction. Option A is incorrect because ACE inhibitors decrease renin
release due to negative feedback. Option C is incorrect; ACE inhibitors dilate efferent arterioles. Option
D is false; they act on different targets.
6. A pharmaceutical company is developing a digital companion app for a new asthma inhaler. The
app tracks medication adherence and provides reminders. The representative is discussing the app
with a physician. Which of the following statements about the regulatory status of such digital tools
is most accurate?
A. The app is considered a medical device and requires FDA clearance before marketing.
B. The app is exempt from FDA regulation because it only provides adherence reminders and does not make
treatment recommendations.
C. The app is classified as a drug-device combination product and must be approved via a single application.
D. The app is regulated by the FTC, not the FDA, because it is a promotional tool.
Answer: B
Rationale: Correct: Under FDA guidance, apps that simply track adherence and provide reminders are
generally not regulated as medical devices, as they do not perform clinical functions. Option A is
incorrect unless the app makes diagnostic or therapeutic recommendations. Option C is incorrect
because it is not a combination product. Option D is incorrect; the FDA regulates software that meets
device definition.
7. A sales representative is preparing a report on the competitive landscape for a novel oral
anticoagulant. The representative needs to compare the drug's efficacy and safety profile to
warfarin and direct oral anticoagulants (DOACs). Which of the following study design features is
most critical for evaluating the drug's net clinical benefit?
A. A non-inferiority trial with a wide margin to demonstrate at least equivalent efficacy.
B. A superiority trial powered for both efficacy and safety endpoints, with a composite of stroke and major
bleeding as the primary outcome.
C. An observational cohort study with propensity score matching to reflect real-world effectiveness.
D. A meta-analysis of several small randomized trials to increase statistical power.
Answer: B
Rationale: Correct: A superiority trial with a composite endpoint of efficacy and safety (net clinical
benefit) provides the most robust evidence for comparing benefit-risk. Option A: non-inferiority with
wide margin may not demonstrate superiority and can be misleading. Option C: observational studies
are subject to confounding despite matching. Option D: meta-analyses can be useful but depend on
quality of included trials; a well-powered single trial is stronger.
8. A sales representative is calling on a rheumatologist who prescribes a biologic for rheumatoid
arthritis. The doctor mentions that several patients have developed neutralizing antibodies to the
drug, leading to loss of efficacy. The representative wants to suggest a strategy to mitigate
immunogenicity. Which of the following approaches is most evidence-based?
Page 3
, A. Switching to a biosimilar of the same biologic, which has lower immunogenicity due to minor structural
differences.
B. Concomitant use of methotrexate, which has been shown to reduce anti-drug antibody formation.
C. Increasing the dose of the biologic to overcome antibody-mediated clearance.
D. Administering the biologic subcutaneously instead of intravenously to reduce immune activation.
Answer: B
Rationale: Correct: Methotrexate is commonly used with biologics in RA and has been shown to reduce
immunogenicity, improving drug persistence. Option A is incorrect; biosimilars have similar
immunogenicity profiles. Option C is not a standard approach and may increase toxicity. Option D:
route of administration can affect immunogenicity, but switching from IV to SC does not consistently
reduce antibodies and may even increase them.
9. A pharmaceutical sales representative is preparing a value dossier for a new
cholesterol-lowering PCSK9 inhibitor. The drug reduces LDL cholesterol by 60% but costs $14,000
per year. The ICER (incremental cost-effectiveness ratio) compared to statins is $150,000 per
QALY gained. Which of the following statements best interprets the ICER and its implications for
formulary access?
A. An ICER of $150,000/QALY is below the commonly accepted US threshold of $200,000/QALY, so the drug
is likely to be covered without restrictions.
B. The ICER indicates the drug is not cost-effective, and payers will likely require prior authorization and
restrict use to high-risk patients.
C. The ICER is irrelevant because QALYs are not used by US payers in coverage decisions.
D. The ICER suggests the drug is cost-saving compared to statins when considering reduced cardiovascular
events.
Answer: B
Rationale: Correct: The commonly cited US cost-effectiveness threshold is around
$100,000-$150,000/QALY, so $150,000/QALY is borderline high, often leading to restricted access.
Option A is incorrect because many payers use lower thresholds. Option C is false; QALYs are used in
value assessments. Option D is incorrect; the drug is not cost-saving as it adds cost with modest QALY
gains.
10. A sales representative is planning a speaker program for a new migraine preventive drug. The
representative wants to ensure compliance with the PhRMA Code on Interactions with Healthcare
Professionals. Which of the following arrangements is most likely to be considered acceptable?
A. Hosting a dinner at a high-end restaurant for 20 physicians, with the representative presenting the drug's
clinical data.
B. Providing an unrestricted educational grant to a medical society to develop a CME program on migraine
management.
C. Paying a well-known neurologist a $5,000 honorarium to speak at a dinner program attended by 10 other
physicians.
D. Offering a $100 gift card to each physician who attends a webinar on the new drug.
Answer: B
Rationale: Correct: Unrestricted educational grants to medical societies for CME are generally
acceptable under the PhRMA Code. Option A: dinners must be modest and the setting should not be
extravagant. Option C: honoraria must be reasonable and not excessive; $5,000 for a small audience
Page 4
